Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 174

1.

BET inhibition as a rational therapeutic strategy for invasive lobular breast cancer.

Walsh L, Haley KE, Moran B, Mooney B, Tarrant F, Madden SF, Di Grande A, Fan Y, Das S, Rueda OM, Dowling CM, Varešlija D, Chin SF, Linn SC, Young LS, Jirström K, Crown J, Bernards R, Caldas C, Gallagher WM, O'Connor DP, Ni Chonghaile T.

Clin Cancer Res. 2019 Aug 13. pii: clincanres.0713.2019. doi: 10.1158/1078-0432.CCR-19-0713. [Epub ahead of print]

PMID:
31409615
2.

Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes.

Sobral-Leite M, Salomon I, Opdam M, Kruger DT, Beelen KJ, van der Noort V, van Vlierberghe RLP, Blok EJ, Giardiello D, Sanders J, Van de Vijver K, Horlings HM, Kuppen PJK, Linn SC, Schmidt MK, Kok M.

Breast Cancer Res. 2019 Aug 7;21(1):90. doi: 10.1186/s13058-019-1176-2.

3.

Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, Nederlof I, Kluin RJC, Warren S, Ong S, Wiersma TG, Russell NS, Lalezari F, Schouten PC, Bakker NAM, Ketelaars SLC, Peters D, Lange CAH, van Werkhoven E, van Tinteren H, Mandjes IAM, Kemper I, Onderwater S, Chalabi M, Wilgenhof S, Haanen JBAG, Salgado R, de Visser KE, Sonke GS, Wessels LFA, Linn SC, Schumacher TN, Blank CU, Kok M.

Nat Med. 2019 Jul;25(7):1175. doi: 10.1038/s41591-019-0520-5.

PMID:
31209337
4.

MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology.

Mittempergher L, Delahaye LJMJ, Witteveen A, Spangler JB, Hassenmahomed F, Mee S, Mahmoudi S, Chen J, Bao S, Snel MHJ, Leidelmeijer S, Besseling N, Lucas AB, Pabón-Peña C, Linn SC, Dreezen C, Wehkamp D, Chan BY, Bernards R, van 't Veer LJ, Glas AM.

J Mol Diagn. 2019 Jun 4. pii: S1525-1578(18)30483-5. doi: 10.1016/j.jmoldx.2019.04.007. [Epub ahead of print]

5.

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, Nederlof I, Kluin RJC, Warren S, Ong S, Wiersma TG, Russell NS, Lalezari F, Schouten PC, Bakker NAM, Ketelaars SLC, Peters D, Lange CAH, van Werkhoven E, van Tinteren H, Mandjes IAM, Kemper I, Onderwater S, Chalabi M, Wilgenhof S, Haanen JBAG, Salgado R, de Visser KE, Sonke GS, Wessels LFA, Linn SC, Schumacher TN, Blank CU, Kok M.

Nat Med. 2019 Jun;25(6):920-928. doi: 10.1038/s41591-019-0432-4. Epub 2019 May 13. Erratum in: Nat Med. 2019 Jun 17;:.

PMID:
31086347
6.

Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study.

van Hellemond IEG, Smorenburg CH, Peer PGM, Swinkels ACP, Seynaeve CM, van der Sangen MJC, Kroep JR, de Graaf H, Honkoop AH, Erdkamp FLG, van den Berkmortel FWPJ, de Boer M, de Roos WK, Linn SC, Imholz ALT, Tjan-Heijnen VCG; Dutch Breast Cancer Research Group (BOOG).

Int J Cancer. 2019 Sep 1;145(5):1325-1333. doi: 10.1002/ijc.32205. Epub 2019 Mar 4.

PMID:
30748011
7.

Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1.

Montemurro F, Ellis P, Anton A, Wuerstlein R, Delaloge S, Bonneterre J, Quenel-Tueux N, Linn SC, Irahara N, Donica M, Lindegger N, Barrios CH.

Eur J Cancer. 2019 Mar;109:92-102. doi: 10.1016/j.ejca.2018.12.022. Epub 2019 Jan 29.

8.

The influence of adjuvant systemic regimens on contralateral breast cancer risk and receptor subtype.

Kramer I, Schaapveld M, Oldenburg HSA, Sonke GS, McCool D, van Leeuwen FE, Van de Vijver KK, Russell NS, Linn SC, Siesling S, Menke-van der Houven van Oordt CW, Schmidt MK.

J Natl Cancer Inst. 2019 Jan 30. doi: 10.1093/jnci/djz010. [Epub ahead of print]

PMID:
30698719
9.

Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES.

Szijgyarto Z, Flach KD, Opdam M, Palmieri C, Linn SC, Wesseling J, Ali S, Bliss JM, Cheang MCU, Zwart W, Coombes RC.

Breast Cancer Res Treat. 2019 May;175(1):149-163. doi: 10.1007/s10549-018-05110-x. Epub 2019 Jan 24.

10.

Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA.

Gao M, Callari M, Beddowes E, Sammut SJ, Grzelak M, Biggs H, Jones L, Boumertit A, Linn SC, Cortes J, Oliveira M, Baird R, Chin SF, Caldas C.

Genome Med. 2019 Jan 4;11(1):1. doi: 10.1186/s13073-018-0611-9.

11.

Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure.

van Hellemond IEG, Vriens IJH, Peer PGM, Swinkels ACP, Smorenburg CH, Seynaeve CM, van der Sangen MJC, Kroep JR, de Graaf H, Honkoop AH, Erdkamp FLG, van den Berkmortel FWPJ, de Boer M, de Roos WK, Linn SC, Imholz ALT, Tjan-Heijnen VCG; Dutch Breast Cancer Research Group (BOOG).

Int J Cancer. 2019 Jul 1;145(1):274-283. doi: 10.1002/ijc.32093. Epub 2019 Jan 16.

12.

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.

van Ramshorst MS, van der Voort A, van Werkhoven ED, Mandjes IA, Kemper I, Dezentjé VO, Oving IM, Honkoop AH, Tick LW, van de Wouw AJ, Mandigers CM, van Warmerdam LJ, Wesseling J, Vrancken Peeters MT, Linn SC, Sonke GS; Dutch Breast Cancer Research Group (BOOG).

Lancet Oncol. 2018 Dec;19(12):1630-1640. doi: 10.1016/S1470-2045(18)30570-9. Epub 2018 Nov 6.

PMID:
30413379
13.

Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences.

Kruger DT, Beelen KJ, Opdam M, Sanders J, van der Noort V, Boven E, Linn SC.

Br J Cancer. 2018 Oct;119(7):832-839. doi: 10.1038/s41416-018-0221-8. Epub 2018 Oct 5.

PMID:
30287915
14.

Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04).

van Rossum AGJ, Kok M, van Werkhoven E, Opdam M, Mandjes IAM, van Leeuwen-Stok AE, van Tinteren H, Imholz ALT, Portielje JEA, Bos MMEM, van Bochove A, Wesseling J, Rutgers EJ, Linn SC, Oosterkamp HM; MATADOR Trialists' Group.

Eur J Cancer. 2018 Oct;102:40-48. doi: 10.1016/j.ejca.2018.07.013.

15.

Nail abnormalities identified in an ageing study of 30 inbred mouse strains.

Linn SC, Mustonen AM, Silva KA, Kennedy VE, Sundberg BA, Bechtold LS, Alghamdi S, Hoehndorf R, Schofield PN, Sundberg JP.

Exp Dermatol. 2019 Apr;28(4):383-390. doi: 10.1111/exd.13759. Epub 2018 Sep 4.

PMID:
30074290
16.

[Freud and colorectal cancer guideline adherence in the Netherlands].

Linn SC.

Ned Tijdschr Geneeskd. 2018 Jul 5;162. pii: D2969. Dutch.

PMID:
30040332
17.

FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome.

Schrijver W, Schuurman K, van Rossum A, Droog M, Jeronimo C, Salta S, Henrique R, Wesseling J, Moelans C, Linn SC, van den Heuvel M, van Diest P, Zwart W.

Mol Oncol. 2018 Nov;12(11):1884-1894. doi: 10.1002/1878-0261.12353. Epub 2018 Oct 12.

18.

Ovarian Function Recovery During Anastrozole in Breast Cancer Patients With Chemotherapy-Induced Ovarian Function Failure.

van Hellemond IEG, Vriens IJH, Peer PGM, Swinkels ACP, Smorenburg CH, Seynaeve CM, van der Sangen MJC, Kroep JR, de Graaf H, Honkoop AH, Erdkamp FLG, van den Berkmortel FWPJ, Kitzen JJEM, de Boer M, de Roos WK, Linn SC, Imholz ALT, Tjan-Heijnen VCG; Dutch Breast Cancer Research Group (BOOG).

J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx074.

PMID:
29546343
19.

Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancer.

Severson TM, Kim Y, Joosten SEP, Schuurman K, van der Groep P, Moelans CB, Ter Hoeve ND, Manson QF, Martens JW, van Deurzen CHM, Barbe E, Hedenfalk I, Bult P, Smit VTHBM, Linn SC, van Diest PJ, Wessels L, Zwart W.

Nat Commun. 2018 Feb 2;9(1):482. doi: 10.1038/s41467-018-02856-2.

20.

Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy.

van Rossum AGJ, Kok M, McCool D, Opdam M, Miltenburg NC, Mandjes IAM, van Leeuwen-Stok E, Imholz ALT, Portielje JEA, Bos MMEM, van Bochove A, van Werkhoven E, Schmidt MK, Oosterkamp HM, Linn SC.

Oncotarget. 2017 Nov 27;8(69):113531-113542. doi: 10.18632/oncotarget.22697. eCollection 2017 Dec 26.

21.

Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study.

Dackus GMHE, Jóźwiak K, Sonke GS, van der Wall E, van Diest PJ, Hauptmann M, Siesling S, Linn SC.

Eur J Cancer. 2018 Feb;90:92-101. doi: 10.1016/j.ejca.2017.11.010. Epub 2017 Dec 21.

22.

Long-term prognosis of young breast cancer patients (≤40 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study.

Dackus GM, Ter Hoeve ND, Opdam M, Vreuls W, Varga Z, Koop E, Willems SM, Van Deurzen CH, Groen EJ, Cordoba A, Bart J, Mooyaart AL, van den Tweel JG, Zolota V, Wesseling J, Sapino A, Chmielik E, Ryska A, Amant F, Broeks A, Kerkhoven R, Stathonikos N, Veta M, Voogd A, Jozwiak K, Hauptmann M, Hoogstraat M, Schmidt MK, Sonke G, van der Wall E, Siesling S, van Diest PJ, Linn SC.

BMJ Open. 2017 Nov 14;7(11):e017842. doi: 10.1136/bmjopen-2017-017842.

23.

PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.

Geenen JJJ, Linn SC, Beijnen JH, Schellens JHM.

Clin Pharmacokinet. 2018 Apr;57(4):427-437. doi: 10.1007/s40262-017-0587-4. Review.

PMID:
29063517
24.

Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.

Tjan-Heijnen VCG, van Hellemond IEG, Peer PGM, Swinkels ACP, Smorenburg CH, van der Sangen MJC, Kroep JR, De Graaf H, Honkoop AH, Erdkamp FLG, van den Berkmortel FWPJ, de Boer M, de Roos WK, Linn SC, Imholz ALT, Seynaeve CM; Dutch Breast Cancer Research Group (BOOG) for the DATA Investigators.

Lancet Oncol. 2017 Nov;18(11):1502-1511. doi: 10.1016/S1470-2045(17)30600-9. Epub 2017 Oct 12. Erratum in: Lancet Oncol. 2017 Nov;18(11):e642.

PMID:
29031778
25.

BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial.

van Rossum AGJ, Schouten PC, Weber KE, Nekljudova V, Denkert C, Solbach C, Köhne CH, Thomssen C, Forstbauer H, Hoffmann G, Kohls A, Schmatloch S, Schem C, von Minckwitz G, Karn T, Möbus VJ, Linn SC, Loibl S, Marmé F.

Breast Cancer Res Treat. 2017 Dec;166(3):775-785. doi: 10.1007/s10549-017-4444-9. Epub 2017 Aug 18.

PMID:
28822007
26.

Impact of 70-Gene Signature Use on Adjuvant Chemotherapy Decisions in Patients With Estrogen Receptor-Positive Early Breast Cancer: Results of a Prospective Cohort Study.

Kuijer A, Straver M, den Dekker B, van Bommel ACM, Elias SG, Smorenburg CH, Wesseling J, Linn SC, Rutgers EJT, Siesling S, van Dalen T.

J Clin Oncol. 2017 Aug 20;35(24):2814-2819. doi: 10.1200/JCO.2016.70.3959. Epub 2017 Mar 13.

PMID:
28813638
27.

Stimulation of the ovaries in women with breast cancer undergoing fertility preservation: Alternative versus standard stimulation protocols; the study protocol of the STIM-trial.

Dahhan T, Balkenende EME, Beerendonk CCM, Fleischer K, Stoop D, Bos AME, Lambalk CB, Schats R, van Golde RJT, Schipper I, Louwé LA, Cantineau AEP, Smeenk JMJ, de Bruin JP, Reddy N, Kopeika Y, van der Veen F, van Wely M, Linn SC, Goddijn M.

Contemp Clin Trials. 2017 Oct;61:96-100. doi: 10.1016/j.cct.2017.07.009. Epub 2017 Jul 11.

PMID:
28710053
28.

Clinically node negative breast cancer patients undergoing breast conserving therapy, sentinel lymph node procedure versus follow-up: a Dutch randomized controlled multicentre trial (BOOG 2013-08).

van Roozendaal LM, Vane MLG, van Dalen T, van der Hage JA, Strobbe LJA, Boersma LJ, Linn SC, Lobbes MBI, Poortmans PMP, Tjan-Heijnen VCG, Van de Vijver KKBT, de Vries J, Westenberg AH, Kessels AGH, de Wilt JHW, Smidt ML.

BMC Cancer. 2017 Jul 1;17(1):459. doi: 10.1186/s12885-017-3443-x.

29.

Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.

Steenbruggen TG, van Ramshorst MS, Kok M, Linn SC, Smorenburg CH, Sonke GS.

Drugs. 2017 Aug;77(12):1313-1336. doi: 10.1007/s40265-017-0774-5. Review.

PMID:
28616845
30.

The effect of manganese exposure in Atp13a2-deficient mice.

Fleming SM, Santiago NA, Mullin EJ, Pamphile S, Karkare S, Lemkuhl A, Ekhator OR, Linn SC, Holden JG, Aga DS, Roth JA, Liou B, Sun Y, Shull GE, Schultheis PJ.

Neurotoxicology. 2018 Jan;64:256-266. doi: 10.1016/j.neuro.2017.06.005. Epub 2017 Jun 6.

PMID:
28595912
31.

Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years.

Engelhardt EG, van den Broek AJ, Linn SC, Wishart GC, Rutgers EJT, van de Velde AO, Smit VTHBM, Voogd AC, Siesling S, Brinkhuis M, Seynaeve C, Westenend PJ, Stiggelbout AM, Tollenaar RAEM, van Leeuwen FE, van 't Veer LJ, Ravdin PM, Pharaoh PDP, Schmidt MK.

Eur J Cancer. 2017 Jun;78:37-44. doi: 10.1016/j.ejca.2017.03.015. Epub 2017 Apr 14.

PMID:
28412587
32.

Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study.

van Ramshorst MS, van Werkhoven E, Mandjes IAM, Schot M, Wesseling J, Vrancken Peeters MTFD, Meerum Terwogt JM, Bos MEM, Oosterkamp HM, Rodenhuis S, Linn SC, Sonke GS.

Eur J Cancer. 2017 Mar;74:47-54. doi: 10.1016/j.ejca.2016.12.023. Epub 2017 Feb 10.

PMID:
28335887
33.

Estrogen receptor α wields treatment-specific enhancers between morphologically similar endometrial tumors.

Droog M, Nevedomskaya E, Dackus GM, Fles R, Kim Y, Hollema H, Mourits MJ, Nederlof PM, van Boven HH, Linn SC, van Leeuwen FE, Wessels LF, Zwart W.

Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):E1316-E1325. doi: 10.1073/pnas.1615233114. Epub 2017 Feb 6. Erratum in: Proc Natl Acad Sci U S A. 2018 Jan 22;:. Mourits, Marian [corrected to Mourits, Marian J].

34.

Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients: Results from the TEAMIIA study (BOOG2006-04).

Fontein DB, Charehbili A, Nortier JW, Putter H, Kranenbarg EM, Kroep JR, Linn SC, van de Velde CJ.

Eur J Surg Oncol. 2017 Apr;43(4):619-624. doi: 10.1016/j.ejso.2016.07.146. Epub 2016 Dec 10.

PMID:
28017458
35.

An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome.

de Vries Schultink AH, Alexi X, van Werkhoven E, Madlensky L, Natarajan L, Flatt SW, Zwart W, Linn SC, Parker BA, Wu AH, Pierce JP, Huitema AD, Beijnen JH.

Breast Cancer Res Treat. 2017 Feb;161(3):567-574. doi: 10.1007/s10549-016-4083-6. Epub 2016 Dec 22.

36.

(Very) Early technology assessment and translation of predictive biomarkers in breast cancer.

Miquel-Cases A, Schouten PC, Steuten LM, Retèl VP, Linn SC, van Harten WH.

Cancer Treat Rev. 2017 Jan;52:117-127. doi: 10.1016/j.ctrv.2016.11.008. Epub 2016 Nov 30. Review.

37.

Low risk of recurrence in elderly patients treated with breast conserving therapy in a single institute.

van der Leij F, van Werkhoven E, Bosma S, Linn SC, Rutgers EJ, van de Vijver MJ, Bartelink H, Elkhuizen PHM, Scholten A.

Breast. 2016 Dec;30:19-25. doi: 10.1016/j.breast.2016.08.004. Epub 2016 Aug 29.

PMID:
27587341
38.

Erratum to: The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.

van Ramshorst MS, van der Heiden-van der Loo M, Dackus GM, Linn SC, Sonke GS.

Breast Cancer Res Treat. 2016 Sep;159(2):393. No abstract available.

PMID:
27534944
39.

Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.

van Ramshorst MS, van Werkhoven E, Honkoop AH, Dezentjé VO, Oving IM, Mandjes IA, Kemper I, Smorenburg CH, Stouthard JM, Linn SC, Sonke GS; Dutch Breast Cancer Research Group (BOOG).

Breast. 2016 Oct;29:153-9. doi: 10.1016/j.breast.2016.07.017. Epub 2016 Aug 5.

PMID:
27498129
40.

The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.

van Ramshorst MS, van der Heiden-van der Loo M, Dackus GM, Linn SC, Sonke GS.

Breast Cancer Res Treat. 2016 Jul;158(2):361-71. doi: 10.1007/s10549-016-3878-9. Epub 2016 Jun 29. Erratum in: Breast Cancer Res Treat. 2016 Sep;159(2):393.

PMID:
27357813
41.

The Melanoma MAICare Framework: A Microsimulation Model for the Assessment of Individualized Cancer Care.

van der Meijde E, van den Eertwegh AJ, Linn SC, Meijer GA, Fijneman RJ, Coupé VM.

Cancer Inform. 2016 Jun 15;15:115-27. doi: 10.4137/CIN.S38122. eCollection 2016.

42.

10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study.

van Maaren MC, de Munck L, de Bock GH, Jobsen JJ, van Dalen T, Linn SC, Poortmans P, Strobbe LJA, Siesling S.

Lancet Oncol. 2016 Aug;17(8):1158-1170. doi: 10.1016/S1470-2045(16)30067-5. Epub 2016 Jun 22.

PMID:
27344114
44.

A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial.

Drooger JC, van Tinteren H, de Groot SM, Ten Tije AJ, de Graaf H, Portielje JE, Jager A, Honkoop A, Linn SC, Kroep JR, Erdkamp FL, Hamberg P, Imholz AL, van Rossum-Schornagel QC, Heijns JB, van Leeuwen-Stok AE, Sleijfer S.

Cancer. 2016 Oct;122(19):2961-70. doi: 10.1002/cncr.30141. Epub 2016 Jun 17.

45.

Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas.

Droog M, Nevedomskaya E, Kim Y, Severson T, Flach KD, Opdam M, Schuurman K, Gradowska P, Hauptmann M, Dackus G, Hollema H, Mourits M, Nederlof P, van Boven H, Linn SC, Wessels L, van Leeuwen FE, Zwart W.

Cancer Res. 2016 Jul 1;76(13):3773-84. doi: 10.1158/0008-5472.CAN-14-1813. Epub 2016 May 6. Erratum in: Cancer Res. 2018 May 1;78(9):2446.

46.

Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation.

Severson TM, Nevedomskaya E, Peeters J, Kuilman T, Krijgsman O, van Rossum A, Droog M, Kim Y, Koornstra R, Beumer I, Glas AM, Peeper D, Wesseling J, Simon IM, Wessels L, Linn SC, Zwart W.

Oncotarget. 2016 Jun 7;7(23):33901-18. doi: 10.18632/oncotarget.8983.

47.

[Living with incurable cancer].

Buiting HM, Linn SC, Smorenburg CH, de Kanter W.

Ned Tijdschr Geneeskd. 2016;160:A9615. Review. Dutch.

PMID:
27122068
48.

Targeted MS Assay Predicting Tamoxifen Resistance in Estrogen-Receptor-Positive Breast Cancer Tissues and Sera.

De Marchi T, Kuhn E, Dekker LJ, Stingl C, Braakman RB, Opdam M, Linn SC, Sweep FC, Span PN, Luider TM, Foekens JA, Martens JW, Carr SA, Umar A.

J Proteome Res. 2016 Apr 1;15(4):1230-42. doi: 10.1021/acs.jproteome.5b01119. Epub 2016 Mar 18.

PMID:
26958999
49.

BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial.

Schouten PC, Gluz O, Harbeck N, Mohrmann S, Diallo-Danebrock R, Pelz E, Kruizinga J, Velds A, Nieuwland M, Kerkhoven RM, Liedtke C, Frick M, Kates R, Linn SC, Nitz U, Marme F.

Int J Cancer. 2016 Aug 15;139(4):882-9. doi: 10.1002/ijc.30078. Epub 2016 May 5.

50.

Ongoing Remission Nineteen Years after High-dose Chemotherapy for Oligometastatic Breast Cancer; What Can We Learn from this Patient?

Steenbruggen TG, Linn SC, Rodenhuis S, Sonke GS.

Cureus. 2015 Dec 24;7(12):e433. doi: 10.7759/cureus.433.

Supplemental Content

Support Center